Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT-BIRISK: Clopidogrel Monotherapy vs DAPT in High-Risk ACS Patients
NCT03431142Phase 4Completed
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of clopidogrel in acute coronary syndrome (ACS) (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Clinical relevant bleeding events at 9 months. Started Feb 2018; status: completed.
02
Drugs
clopidogrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03431142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431142.